Table 2.

Treatment details

Variable	Value
N of cycles of AA, median (range)	10 (1–35)
Last PSA, median (range), n = 130	9.7 (0.0 to 2743.0)
12 weeks PSA, median (range), n = 99	7.7 (0.0 to 900.0)
12 weeks PSA decline, n (%), n = 99	49 (49.5)
12 weeks ALT, median (range), n = 58	22 (88–215)
12 weeks AST, median (range), n = 58	23 (9–150)
Patients’ subjective impression on AA regimen, n = 108 (missing =27)
1 = greatly improved	35 (32.4)
2 = improved	41 (37.9)
3 = not changed	26 (24.0)
4 = worsened	6 (5.5)
Median follow-up time, month (IQR)	13.6 (7–16)
Death, n (%)	33 (22.8)
Progression, n (%)	56 (38.6)
Median PFS, month (95% CI)	18.5 (16–20)
Median OS, month (95% CI)	26.5 (21–32)

Abreviations: PSA prostate specific antigen, AA abiraterone acetate, ALT alanine aminotransferase, AST aspartate aminotransferase, PFS progression free survival, OS overall survival